Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2146806 | 0.92 | ALDH1A1 (0.55) | ALDH1A1CYP2C9L3MBTL1KDM4ETSHR | |
| SCHEMBL2146803 | 0.92 | ALDH1A1 (0.55) | ALDH1A1CYP2C9L3MBTL1KDM4ETSHR | |
| Hydrochloric Acid SCHEMBL21640110 | 0.86 | ALDH1A1 (0.56) | ALDH1A1CYP2C9L3MBTL1KDM4ETSHR | |
| SCHEMBL2148739 | 0.84 | LMNA (0.53) | ALDH1A1CYP2C9KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL2148732 | 0.84 | LMNA (0.53) | ALDH1A1CYP2C9KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL24322786 | 0.84 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1TSHRSMN1; SMN2KMT2A | |
| SCHEMBL15362709 | 0.83 | ALDH1A1 (0.61) | ALDH1A1CYP2C9L3MBTL1KDM4ETSHR | |
| SCHEMBL19849348 | 0.83 | ALDH1A1 (0.71) | ALDH1A1CYP2C9L3MBTL1KDM4ETSHR | |
| Hydrochloric Acid SCHEMBL2146359 | 0.83 | LMNA (0.52) | ALDH1A1CYP2C9KDM4ESMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL2146368 | 0.83 | LMNA (0.52) | ALDH1A1CYP2C9KDM4ESMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | ALDH1A1 4556/4885CYP2C9 4549/4885L3MBTL1 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.